Skip to main content
Clinical Trials/CTRI/2021/12/038384
CTRI/2021/12/038384
Not yet recruiting
Phase 2

A Prospective study Randomized Comparative clinical study to evaluate the safety and efficacy of synergistic plant metabolite Combination tablets in Type II Diabetes mellitus patients

Apex laboratories private limited0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: E119- Type 2 diabetes mellitus without complications
Sponsor
Apex laboratories private limited
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Male or female patients within the age range of 40 to 60 years (both years inclusive) diagnosed with T2DM for at least 3 months.
  • Willingness to provide written informed consent to participate in the study.
  • Patients understanding the nature and purpose of the study and who are willing to comply with study procedures.
  • Fasting plasma glucose greater than or equal to 126 mg/dL
  • Random plasma glucose greater than 200 mg/dL in a person with symptoms of diabetes.
  • Duration of diabetes â?? Newly diagnosed diabetics or diagnosed within past 2 years
  • HbA1C between 6\.5 \- 9\.5%

Exclusion Criteria

  • Type 1 diabetes mellitus
  • Patients with severe hyperglycemia (FBS \>234 mg% or PPBS \> 360 mg%)
  • Fasting serum cholesterol \>260mg% and serum Triglycerides \>300 mg%.
  • HbA1C more than 9\.5 %.
  • AST and ALT levels greater than 2\.5 times the upper normal limits
  • Severe renal, hepatic, cardiac, gastrointestinal, neurological, hematological or respiratory disorders, in view of the investigator.
  • Patients with psychiatric disorder.
  • History of smoking (more than 10 cigarettes/day) or alcohol intake
  • History or evidence suggestive of complications of diabetes such as • Retinopathy • Nephropathy • Presence of ketone bodies in urine analysis • Ischemic heart disease with any cardiac event in last 6 months • Neuropathy
  • BMI \>35 kg/m2 or less than 20 kg/m2

Outcomes

Primary Outcomes

Not specified

Similar Trials